Denali Therapeutics Inc. Deferred Tax Assets, Operating Loss Carryforwards
Denali Therapeutics Inc. (DNLI) had Deferred Tax Assets, Operating Loss Carryforwards of $229.53 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $229.53M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $113.40M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $89.27M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $67.49M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $229.53M 10-K · filed 2026-02-26 |
| 2024-12-31 | $113.40M 10-K · filed 2026-02-26 |
| 2023-12-31 | $89.27M 10-K · filed 2025-02-27 |
| 2022-12-31 | $67.49M 10-K · filed 2024-02-28 |
| 2021-12-31 | $59.28M 10-K · filed 2023-02-27 |
| 2020-12-31 | $54.11M 10-K · filed 2022-02-28 |
| 2019-12-31 | $56.61M 10-K · filed 2021-02-26 |
| 2018-12-31 | $35.02M 10-K · filed 2020-02-27 |
| 2017-12-31 | $37.61M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |